Corruption in The Medical Field: US Doctors Threatened Over Hydroxychlorquine Use. Dr. Fauci is Blocking HCQ

There is an ongoing battle to suppress Hydroxychloroquine (HCQ), a cheap and effective drug for the treatment of Covid-19. Dr. Anthony Fauci, advisor to president Trump has played a central role in blocking HCQ.  

On May 22, an “authoritative” peer reviewed “evaluation” of HCQ was published in The Lancet. The study was allegedly based on data analysis of 96,032 patients hospitalized with COVID-19 from 671 hospitals Worldwide.  That database had been fabricated. The Lancet study was “Retracted”. The objective of that fake study, quoted by the media (as well as by Dr. Anthony Fauci) was to kill the Hydroxychloroquine (HCQ) cure on behalf of Big Pharma.

And now, as documented by Fox News, US medical doctors are being threatened by the State Medical Licensing Boards not to prescribe HCQ, an effective treatment for COVID.

“75,000 to 100,000 lives would be saved” if the ban on HCQ is lifted said Yale Professor of Epidemiology Dr. Harvey Risch  (Interview below)

There is a media blackout on HCQ. “So much corruption in the medical field when it comes to bureaucrats” says Laura Ingraham.

And guess who was involved in blocking the use of HCQ. Dr. Anthony Fauci, advisor to president Trump.

VIDEO

Dr. Fauci had earlier stated categorically that the use of HCQ had not been studied in relation to the coronavirus. “No proven drug”: “Not Enough Known”.  . That’s a “False Statement”.

What Fauci failed to mention is that Chloroquine had been tested fifteen years ago by the CDC as a drug to be used against coronavirus infections.  Chloroquine was used in 2002 and tested against SARS-1 coronavirus in a study under the auspices of the CDC published in 2005 in the peer reviewed Virology Journal. The main conclusion of the article was that:  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. It was used in the SARS-1 outbreak in 2002. It had the endorsement of the CDC.

The ban on HCQ was intended to promote a $1.6 Billion HHS Contract with Big Pharma’s Gilead Sciences Inc

Dr. Anthony Fauci, head of the NIAID granted the “Greenlight” to Gilead Sciences Inc. based on the  “preliminary” findings NIH-NIAID study (May 22) which he coordinated: Remdesivir for the Treatment of Covid-19 — Preliminary Report (NEJM). 

Who will be able to afford Remdisivir? Ask Dr. Fauci.

500,000 doses of Remdesivir are envisaged at $3,200 per patient, namely $1.6 billion

(For further details see

LancetGate: “Scientific Corona Lies” and Big Pharma Corruption. Hydroxychloroquine versus Gilead’s Remdesivir

By Prof Michel Chossudovsky, July 13, 2020

 


Comment on Global Research Articles on our Facebook page

Become a Member of Global Research


About the author:

Michel Chossudovsky is an award-winning author, Professor of Economics (emeritus) at the University of Ottawa, Founder and Director of the Centre for Research on Globalization (CRG), Montreal, Editor of Global Research.  He has taught as visiting professor in Western Europe, Southeast Asia, the Pacific and Latin America. He has served as economic adviser to governments of developing countries and has acted as a consultant for several international organizations. He is the author of eleven books including The Globalization of Poverty and The New World Order (2003), America’s “War on Terrorism” (2005), The Global Economic Crisis, The Great Depression of the Twenty-first Century (2009) (Editor), Towards a World War III Scenario: The Dangers of Nuclear War (2011), The Globalization of War, America's Long War against Humanity (2015). He is a contributor to the Encyclopaedia Britannica.  His writings have been published in more than twenty languages. In 2014, he was awarded the Gold Medal for Merit of the Republic of Serbia for his writings on NATO's war of aggression against Yugoslavia. He can be reached at [email protected]

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]